Rocket Lab: Wall Street's $232 Million Expectation Is Already Baked Into a 73x Sales Multiple

Wall Street wants $231.6 million in revenue and 60% growth from Rocket Lab when it reports Q2 earnings Monday night. That's a tall ask on paper. In reality, it's right inside management's own $225 million to $240 million guidance. The quarter won't be a surprise — it's been telegraphed.

The real question isn't whether Rocket Lab hits the number. It's whether the market's $49.5 billion valuation can survive the answer.

Rocket Lab stock closed Friday at $82.83, up 9.5% on the day and 27.5% over five days. The catalyst was straightforward: a $397 million Space Force contract announced Thursday for the Space-Based Airborne Moving Target Indicator program, adding to a string of 2026 defense wins that also includes a $266 million suborbital launch deal and the $816 million Space Development Agency Tracking Layer award. The backlog sits at roughly $2.2 billion. The pipeline looks impressive.

But the stock has gained 85.5% over the past 12 months and is trading at 72.9 times trailing sales. That multiple prices in a company that has already won the medium-lift launch market, scaled satellite manufacturing profitably, and turned Neutron — its reusable medium-lift rocket — into a margin-accelerating revenue engine within the next couple of years. None of those things have happened yet. The valuation is a prediction, not a reflection of current economics.

The growth is real. The cash burn is too.

Revenue growth is genuinely strong. Full-year 2025 revenue reached $602 million, up 38% from the prior year. Q1 2026 came in at $200.3 million, a 63.5% year-over-year jump. Gross margins expanded to 38.2% GAAP in Q1, a record. The Space Systems segment — satellite manufacturing and components — is scaling fast, and the defense contract book is now $1.3 billion and growing.

But the profit picture tells a different story. Operating margin sits at negative 33.2%. Free cash flow for the trailing twelve months is negative $316.3 million. Free cash flow growth year-over-year is negative 78.6%. The company has $1.2 billion in cash on the balance sheet, which provides runway, but at the current burn rate that's roughly four years of operating capital without additional fundraising or a fundamental step-change in unit economics.

That step-change depends on Neutron.

Neutron: the engine of the bull case, the anchor of the risk

Neutron is Rocket Lab's shot at competing in the medium-lift launch market alongside SpaceX's Falcon 9. A 13-ton payload capacity to low-Earth orbit, reusability, and a lower cost per kilogram would unlock the higher-margin constellation deployment market and reduce Rocket Lab's reliance on Electron, its smaller and lower-margin launch vehicle.

Neutron's first launch is now targeted for no earlier than Q4 2026. The debut was pushed back after a first-stage propellant tank ruptured during a hydrostatic pressure test in January. The failure traced to a manufacturing defect in a critical joint — specifically, manual hand-laying of composite tank sections by a contractor. The fix involves switching to automated fiber placement and running a fresh qualification campaign.

Multiple delays are the norm for new launch vehicles. That doesn't make them harmless. Each quarter of delay adds to the cash burn while the stock's valuation demands the rocket be the growth engine now, not later. The $397 million Space Force contract that just sent shares soaring is contingent on Neutron's success — the satellites it's meant to carry can't deploy without it. If Neutron slips further, or if the first flight underperforms, the fixed-price nature of government contracts means Rocket Lab absorbs the overrun risk.

The price action doesn't help

The stock is trading below its 50-day moving average of $90.55 and above its 200-day moving average of $77.98. The MACD is negative at minus 3.66, and the RSI sits at 56 — neutral territory, not momentum. The five-day surge to $82.83 came on a single contract headline, not on an earnings beat or Neutron progress. That's the pattern of a stock where the narrative is outrunning the fundamentals.

The Zacks Rank sits at 4, which is the sell signal in that system, and the quantitative model shows no earnings surprise probability. AInvest's aggregate consensus labels the stock a Buy, but that rating is built on forward growth projections that assume Neutron delivers on schedule and margins expand at the pace the market has already priced in.

What Monday's numbers can and can't do

If Rocket Lab reports revenue in the $230-to-$235 million range and a loss per share near the expected negative $0.03, the report will be broadly in line. That won't move the needle. The market has arguably baked in a doomsday narrative — nothing at all. It's baked in perfection. A clean quarter inside guidance is the baseline, not a catalyst.

What would move the stock higher would be a Neutron timeline upgrade. A credible Q3 2026 or early 2026 first-flight target, or a material margin expansion surprise from Space Systems, would validate the premium. But given the January setback and the company's stated emphasis on thorough qualification, a timeline upgrade in the Q2 call is unlikely.

What would move it lower would be a guidance cut, a Neutron delay to 2027, or a margin miss that signals the Mynaric and Motiv acquisitions are weighing on profitability faster than expected.

The posture

I don't think investors need to chase this earnings. The setup is the opposite of a contrarian buying opportunity. The growth is real, the backlog is impressive, and the defense positioning is genuinely strong. But the valuation is already pricing in a company that's closer to profitability and Neutron-powered scale than the balance sheet and cash flow suggest. At 73 times sales with a negative free cash flow margin of 46.5%, the stock needs years of flawless execution to justify its current price.

Existing holders shouldn't feel compelled to exit entirely, but trimming exposure ahead of Monday's report or after a post-earnings pop raises the average exit price and reduces risk. For investors on the sidelines, the better risk/reward is likely on a deeper pullback — ideally below the 200-day moving average, where the 20-month trend support sits near $78 — or after Neutron's first flight de-risks the single largest assumption baked into this multiple.

I'd reassess if Neutron gets delayed beyond Q4 2026 or if Q2 guidance for Q3 signals a slowdown in the Space Systems ramp. Those would be structural cracks, not just valuation ones.

For now, the market is demanding that a company burning $316 million a year and months from its most important product launch trade like one that's already turned the corner. That's a lot to ask of a beat.